Tag:
elvitegravir
Latest Headlines
Latest Headlines
Gilead faces high hopes for "Quad" as it hatches big expansion plan
Gilead ( $GILD ) will have to clear a high hurdle for its new HIV treatment to meet analysts' expectations. After leaving investors a bit deflated by its first set of pivotal data last month--which
Gilead's blockbuster HIV combo hopeful "Quad" clears PhIII hurdle
Gilead's four-drug "Quad" pill for HIV--its planned successor to the blockbuster Atripla and the lynchpin to its strategy to remain perched on top of the HIV market--cleared an important hurdle today
Gilead's HIV drug aces Ph3 comparison test with Isentress
Gilead Sciences says that its once-daily HIV drug elvitegravir hit its primary endpoint in a late-stage study, demonstrating its non-inferiority to Merck's twice-daily Isentress after 48 weeks of
